Home
About
- Overview
- Team
- Investors
Science
Pipeline
Partners
News & Events
Contact
Menu Menu

Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS

16 January 2026

ALS News Today

https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Mitochondria-1.webp 350 700 Webadm https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png Webadm2026-01-16 08:00:242026-08-14 12:44:40Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS

© NRG Therapeutics

Terms & Conditions
Privacy Policy

44th Annual J.P. Morgan Healthcare Conference

Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical ...